Akers Biosciences sets up Kenya deal, predicts profit
This article was originally published in Clinica
Executive Summary
In common with many of its healthcare counterparts, point of care diagnostics producer Akers Biosciences has seen its share price under pressure this year. Since its AIM launch in London in May 2002 (see Clinica No 1008, p 14), the US company's price has slipped from an opening 135p ($2.10) to 53p. CEO Ray Akers, on a visit to London last week, told Clinica: "We're not alone in experiencing declining share prices."
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.